×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: ALS Combination Therapy Matrix
mechanism
3,214 words
KG: ent-dise-93f3d65f
2026-03-24
kind:mechanism
section:mechanisms
state:published
Contents
ALS Combination Therapy Matrix
⚙
Mechanism Info
Name
ALS Combination Therapy Matrix
Summary
Comprehensive matrix of combination therapy approaches for amyotrophic lateral sclerosis, including mechanisms, targets, and clinical trial status
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
SASP-Mediated Complement Cascade Amplification
Score: 0.70
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Phase-Separated Organelle Targeting
Score: 0.52
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Stress Granule Phase Separation Modulators
Score: 0.49
Vagal Afferent Microbial Signal Modulation
Score: 0.52
Cryptic Exon Silencing Restoration
Score: 0.46
RNA Granule Nucleation Site Modulation
Score: 0.48
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Vocal Cord Neuroplasticity Stimulation
Score: 0.50
Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Score: 0.69
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43
Score: 0.60
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
PARP1 Inhibition Therapy
Score: 0.58
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.51
Show 25 more
Related Analyses (30)
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed
What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed
What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the molecular signatures that distinguish protectiv
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Show 25 more
Related Experiments (30)
cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85
cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80
s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
validation · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Experiment Index
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
TLR4 Antagonists for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Tirzepatide and Dual GIP/GLP-1 Agonists for Neurodegene
therapeutic · Pages share 3 hypotheses
SYK Kinase Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
STING Inhibitor Therapy in Neurodegeneration
therapeutic · Pages share 3 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapy for Ne
therapeutic · Pages share 3 hypotheses
Somatostatin Receptor Modulator Therapy in Neurodegener
therapeutic · Pages share 3 hypotheses
Advanced Neuroimmune Interface and Glial-Neuronal Cross
therapeutic · Pages share 3 hypotheses
Section 147 Neuroimmune Interface and Glial-Neuronal Cr
therapeutic · Pages share 3 hypotheses
RIPK1 Inhibitors for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Precision Medicine Approaches for Neurodegeneration
therapeutic · Pages share 3 hypotheses
P2X7 Receptor Antagonists for Neurodegeneration
therapeutic · Pages share 3 hypotheses
nfat-pathway-modulators-neurodegeneration
therapeutic · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
therapeutic · Pages share 3 hypotheses
Neuroinflammation Modulation Therapies for Neurodegener
therapeutic · Pages share 3 hypotheses
Show 10 more